Log in

OTCMKTS:ABMCAmerican Bio Medica Stock Price, Forecast & News

+0.02 (+8.42 %)
(As of 05/29/2020 04:00 PM ET)
Today's Range
Now: $0.26
50-Day Range
MA: $0.18
52-Week Range
Now: $0.26
Volume1.61 million shs
Average Volume679,575 shs
Market Capitalization$9.23 million
P/E RatioN/A
Dividend YieldN/A
American Bio Medica Corporation develops, manufactures, and sells lateral flow immunoassay tests primarily for the immediate detection of drugs in urine and oral fluids at the point of collection. Its drugs detection products in urine include Rapid Drug Screen, a rapid drug test, which detects the presence or absence of 2 to 10 drugs; Rapid ONE product line that consists of single drug tests, each of which tests for the presence or absence of a single drug; RDS InCup, a drug-testing cup that detects the presence or absence of 1 to 12 drugs; Rapid TOX, a drug test in a cassette platform, which detects the presence or absence of 2 to 10 drugs; Rapid TOX Cup II, a drug testing cup that detects the presence or absence of 1 to 14 drugs; and Rapid TOX Cup II (2G), a second generation of the original Rapid TOX Cup II, which consists of a smaller cup with smaller test strip, as well as private labeled versions of Rapid TOX. The company also offers OralStat, a drug test for the detection of drugs in oral fluids, as well as private labeled versions of OralStat. In addition, the company distributes other products for the detection of substances of abuse; and products that detect the presence or absence of alcohol, and alternative sample options for drug testing, as well as toxicology management services. Further, it provides bulk test strip contract manufacturing services to non-affiliated diagnostic companies. American Bio Medica Corporation serves rehabilitation/drug treatment, pain management, other clinical, government, and employment/workplace markets in the United States and internationally. The company was formerly known as American Micro Media, Inc. and changed its name to American Bio Medica Corporation in September 1992. American Bio Medica Corporation was founded in 1986 and is based in Kinderhook, New York.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.50 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolOTCMKTS:ABMC



Sales & Book Value

Annual Sales$3.87 million


Net Income$-1,030,000.00


Market Cap$9.23 million
Next Earnings Date6/1/2020 (Estimated)
OptionableNot Optionable

Receive ABMC News and Ratings via Email

Sign-up to receive the latest news and ratings for ABMC and its competitors with MarketBeat's FREE daily newsletter.

American Bio Medica (OTCMKTS:ABMC) Frequently Asked Questions

How has American Bio Medica's stock been impacted by COVID-19 (Coronavirus)?

American Bio Medica's stock was trading at $0.0628 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ABMC stock has increased by 310.0% and is now trading at $0.2575. View which stocks have been most impacted by Coronavirus.

When is American Bio Medica's next earnings date?

American Bio Medica is scheduled to release its next quarterly earnings announcement on Monday, June 1st 2020. View our earnings forecast for American Bio Medica.

How were American Bio Medica's earnings last quarter?

American Bio Medica Co. (OTCMKTS:ABMC) announced its quarterly earnings data on Monday, May, 14th. The company reported ($0.01) EPS for the quarter. The business had revenue of $1.04 million for the quarter. View American Bio Medica's earnings history.

Has American Bio Medica been receiving favorable news coverage?

Media coverage about ABMC stock has trended negative recently, InfoTrie Sentiment reports. The research group rates the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. American Bio Medica earned a media sentiment score of -2.4 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutAmerican Bio Medica.

Who are some of American Bio Medica's key competitors?

What other stocks do shareholders of American Bio Medica own?

Who are American Bio Medica's key executives?

American Bio Medica's management team includes the following people:
  • Ms. Melissa A. Waterhouse, CEO, Principal Financial Officer & Director (Age 48)
  • Ms. Jean Neff, Corp. Sec. & Independent Director (Age 76)
  • Mr. Douglas Casterlin, VP of Operations (Age 71)
  • Dr. Scott D. Hutton, VP of Sales & Marketing (Age 62)
  • Mr. J. Duncan Urquhart, Controller (Age 65)

What is American Bio Medica's stock symbol?

American Bio Medica trades on the OTCMKTS under the ticker symbol "ABMC."

How do I buy shares of American Bio Medica?

Shares of ABMC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is American Bio Medica's stock price today?

One share of ABMC stock can currently be purchased for approximately $0.26.

How big of a company is American Bio Medica?

American Bio Medica has a market capitalization of $9.23 million and generates $3.87 million in revenue each year. American Bio Medica employs 41 workers across the globe.

What is American Bio Medica's official website?

The official website for American Bio Medica is www.abmc.com.

How can I contact American Bio Medica?

American Bio Medica's mailing address is 122 SMITH ROAD, KINDERHOOK NY, 12106. The company can be reached via phone at 518-758-8158 or via email at [email protected]

This page was last updated on 5/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.